UNH Stock Recent News

Next week marks the beginning of another earnings season. This is a time when stocks can move sharply as investors process and act on a company's results and guidance.

CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

UnitedHealth Group, Inc. UNH appointed a new head of its Medicaid division, a position that had been unfilled since May.

UNH faces a DOJ criminal probe over its HouseCalls billing, raising stakes for the Medicare Advantage giant.

UnitedHealth Group Incorporated faces significant uncertainty due to an active DOJ investigation and ongoing Medicare Advantage margin pressures, clouding near-term prospects. UNH Q1 earnings disappointed across all metrics, with management withdrawing guidance, highlighting operational challenges and lack of visibility. Insider buying has surged, signaling some internal confidence, while the stock trades at historically cheap valuations if issues prove temporary.

If you're an income-seeking investor, a buoyant stock market near its all-time high is actually a problem. At recent prices, the average stock in the benchmark S&P 500 index offers an itty-bitty 1.2% dividend yield.

The investigation, which dates back to at least last summer, concerns alleged efforts to encourage staffers to record certain diagnoses that trigger higher payments under Medicare Advantage, according to a report.

The Investment Committee give you their top stocks to watch for the second half.